-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II

Symposia: Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

Kasiani C Myers, MD1, Jie He, MS2*, Ben Goldberg, MS2*, Christopher R. Reilly, MD3, Yang Wan, MD PhD4*, Xiaofan Zhu, MD4,5,6, Simone Cesaro, MD7*, Marco Cipolli, MD8*, Alison A. Bertuch, MD, PhD9,10, Candelaria O'Farrell, MD11,12, Kenichiro Watanabe, MD, PhD13*, Antonis Kattamis, MD14, Polyxeni Delaporta, MD15*, Melanie Cotter, MB16, Eoghan Dunlea, MD17,18*, Taizo A. Nakano, MD19, Amy E. Geddis, MD, PHD20*, Karyn Brundige, MSN, CPNP21*, Ian Atkinson22*, Katherine Coyne21*, Sara Loveless1*, Leah Cheng21*, Edie Weller, PhD2,23*, Jean Donadieu24 and Akiko Shimamura, MD, PhD25

1Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
2Biostatistics and Research Design Center at BCH and Department of Pediatrics at Harvard Medical School, Boston, MA
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Department of Pediatric Hematology and Oncology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College, Tianjin, China
5Childhood Bone Marrow Failure Diseases Register of China Alliance for Blood Diseases, Tianjin, China
6Tianjin Institutes of Health Science, Tianjin 301600, China
7Pediatric Hematology-Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
8Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
9Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX
10Texas Children's Hospital, Houston, TX
11Texas Children’s Hospital, Houston, TX
12Texas Children's Hospital / Baylor College of Medicine, Houston, TX
13Department of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, SHZ, JPN
14Division of Pediatric Hematology-Oncology, First Department of Pediatrics, "Aghia Sophia" Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece
15Thalassemia Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece
16Trinity College, Dublin, Ireland
17Trinity College, Department of Paediatrics, Dublin, Ireland
18Children's Health Ireland, Department of Haematology, Dublin, Ireland
19Children's Hospital Colorado, Denver, CO
20Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, WA
21Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA
22Dana-Farber and Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
23Harvard Medical School, Department of Pediatrics, Boston, MA
24French Reference Center for Histiocytosis, Department of Pediatric Hematology and Oncology, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France
25Boston Children's Hospital, Boston, MA

Enrico Attardi, MD1,2*, Nathan Gray, PA-C1*, Sara Lewis, MS, CGC1*, Michelle Boals, NP1*, Peng Li, MD, PhD3, Erica F. Andersen, PhD, FACMG3, Jian Zhao, PhD3*, Lucilla Pizzo, PhD3*, Bo Hong, MD, FACMG3, Passant Shaker, MD, CGC1*, Rohith Jesudas, MD1*, Lili Kotmayer, MD, PhD1*, Sushree Sahoo, PhD4, Richa Sharma, MD1, Georgios E. Christakopoulos, MD1*, Alyssa Kennedy, MD, PhD1*, Senthil Velan Bhoopalan, MD, PhD1*, Clifford M. Takemoto, MD1, Maria Teresa Voso, MD5 and Marcin Wlodarski, MD, PhD4

1Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN
2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
3ARUP Laboratories, Salt Lake City, UT
4St. Jude Children's Research Hospital, Memphis, TN
5Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

Gary Kupfer1, Paymon Doroodian2*, Jian Li3*, Erica Golemis4*, Paul Young5*, Emily Stahl6*, Arvin Nagarajan6*, Patrick Sung7* and Barbara Burtness8*

1Department of Oncology, Georgetown University, Washington, DC
2Georgetown University, Washington
3Chengdu Universtity, Sichuan, China
4Fox Chase Cancer, Philedelphia, PA
5Rockefeller University, New york, NY
6Georgetown University, Washington, DC
7UT Health San Antonio, San Antonio, TX
8Yale University, New Haven, CT

Shigeki Hirabayashi1, Momoka Tsuruhara1*, Kyoko Fukushi1*, Shoko Tarumoto2*, Moe Shinagawa2*, Yuichiro Semba, MD, PhD1*, Takuya Yamamoto, PhD2,3,4*, Yuichi Shiraishi, PhD5*, Kiyoko Miyata, PhD1*, Taro Tsujimura, PhD2* and Takahiro Maeda, MD, PhD1

1Division of Precision Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
2Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan
3Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, JPN
4Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan
5Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan

Vinicius S. Carvalho, MSc1*, Flávia S. Donaires, PhD2*, Maria Florencia Tellechea, PhD3*, Barbara A. Santana, PhD4*, Guy Sauvageau, MD/PhD5 and Rodrigo T. Calado, MD, PhD6

1Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto, Brazil
2Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, BRA
3Institute for Research in Immunology and Cancer, University of Montreal, Montreal, QC, Canada
4University of Sao Paulo, Ribeirao Preto, BRA
5Universite de Montreal, Montreal, QC, CAN
6University of Sao Paulo, Ribeirão Preto, Brazil

Maria Gabarrós-Subirà1*, Carlos Pérez Míguez2*, Sandra Novoa Jáuregui, MD3*, Jose Angel Díaz-Arias4*, Tzu Hua Chen, MD5*, Sara Torres-Esquius, MSc6*, Araceli Sama-Barroso7*, Helena Pomares8*, Teresa Ezponda9*, Montserrat Arnan, MD, PhD10*, Maria Diez-Campelo, MD, PhD11*, Davide Crucitti12*, Ana Alfonso Pierola, MD, PhD13*, Mónica Del Rey14*, Laura Palomo15*, Francesc Bosch, MD, PhD16, David Valcárcel Ferreiras17*, Julia Montoro18*, Adrian Mosquera Orgueira, MD, PhD19* and Andres Jerez, MD, PhD16*

1Department of Hematology, University Hospital Vall d’Hebron, Barcelona, España., Barcelona, Spain
2Computational Hematology & Genomics Group (GrHeCo-Xen), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
3Hematology Department, Vall d'Hebron University Hospital, University Autònoma of Barcelona (UAB), Barcelona, Spain
4Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
5Hematology and Medical Oncology Department, University Hospital Morales Meseguer. CRH-IMIB, Murcia, Spain
6Vall d'Hebron University Hospital, Barelona, AL, Spain
7Department of hematology, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
8Clinical Hematology Department, ICO-Hospitalet, Hospital Durán i Reynals. IDIBELL, Barcelona., Barcelona, Spain
9Department of Oncology-Hematology, Centro de Investigación Médica Aplicada (CIMA), Navarra university-IDISNA. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC. Clínica Universidad de Navarra, Pamplona, ESP
10Hematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals, Hospitalet de Llobregat, Spain
11University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Department of Hematology - Hospital Universitario de Salamanca, Salamanca, Spain
12Health Research Institute of Santiago de Compostela (IDIS), Santiago De Compostela, Spain
13Hematology and Cell Therapy Department, Clinica Universidad de Navarra, Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain
14Department of Hematology, Salamanca-IBSAL University Hospital, Salamanca, Spain
15CO-Hospital Germans Trias i Pujol, Barcelona, Spain
16Department of Hematology, Experimental Hematology Unit, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Barcelona, Spain
17Experimental Hematology Unit, Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, University Autonoma of Barcelona (UAB), Barcelona, Spain
18Hospital Universitari Vall d'Hebron, Barcelona, Spain
19University Hospital of Santiago de Compostela, Department of Hematology, IDIS, SANTIAGO DE COMPOSTELA, Spain

Sara Torres-Esquius, MSc1*, Guillermo Ramil López, MD2*, Maria Gabarros Subira3*, Pamela Acha4*, Sandra Novoa Jáuregui, MD5*, Marta Pratcorona, MD, PhD2*, Silvia Saumell, MD, PhD6*, David Valcarcel, MD, PhD7, Andres Jerez, MD, PhD8* and Maria Julia Montoro, MD, PhD9*

1Vall d'Hebron University Hospital, Barelona, AL, Spain
2Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
3Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain / España, Spain
4Experimental Hematology, Hospital Universitario Vall d’Hebrón, Institut d’Oncologia Vall d’Hebrón (VHIO), Barcelona, Spain
5Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
6Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain
7Department of Hematology and Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain
8Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
9Experimental Hematology. Hematology Department Vall d´Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebrón, BARCELONA, Spain

Alexandra Prosser, MD1, Irina Pushel, PhD2*, Chris Seidel, PhD3*, Jacqelyn Nemechek, PhD1*, Molly Leyda1*, Priyanka Prem Kumar4*, Jay Vivian, PhD4*, Jennifer Gerton3* and John M. Perry, PhD1

1Division of Hematology/Oncology/Bone Marrow Transplant, Children's Mercy Kansas City, Kansas City, MO
2Genomic Medicine Center, Children's Mercy Kansas City, Kansas City, MO
3Stowers Institute for Medical Research, Kansas City, MO
4Division of Clinical Genetics, Children's Mercy Kansas City, Kansas City, MO

*signifies non-member of ASH